NCT05680233 - Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

July 2, 2024

Study Completion Date

July 2, 2024

Conditions

Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver

Interventions

DRUG

OA-235i (4 mg)

3 participants will receive 4 mg as a single subcutaneous dose

DRUG

OA-235i (8 mg)

3 participants will receive 8 mg as a single subcutaneous dose

DRUG

OA-235i (16 mg)

3 participants will receive 16 mg as a single subcutaneous dose

DRUG

OA-235i (30 mg)

3 participants will receive 30 mg as a single subcutaneous dose

DRUG

OA-235i (40 mg)

3 participants will receive 40 mg as a single subcutaneous dose

DRUG

OA-235i or placebo

9 participants will receive a daily subcutaneous dose of OA-235i or placebo for 7 consecutive days

Trial Locations (1)

Mayo Clinic, Rochester